The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Amyloidosis: Pathogenesis and New Therapeutic Options
Open accessAbstract
The systemic amyloidoses are a group of complex diseases caused by tissue deposition of misfolded proteins that results in progressive organ damage. The most common type, immunoglobulin light chain amyloidosis (AL), is caused by clonal plasma cells that produce misfolded light chains. The purpose of this review is to provide up-to-date information on diagnosis and treatment options for AL amyloidosis. Early, accurate diagnosis is the key to effective therapy, and unequivocal identification of the amyloidogenic protein may require advanced technologies and expertise. Prognosis is dominated by the extent of cardiac involvement, and cardiac staging directs the choice of therapy. Treatment for AL amyloidosis is highly individualized, determined on the basis of age, organ dysfunction, and regimen toxicities, and should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in almost two thirds of patients. Novel agents are also active, and trials are ongoing to establish their optimal use. Treatment algorithms will continue to be refined through controlled trials. Advances in basic research have led to the identification of new drug targets and therapeutic approaches, which will be integrated with chemotherapy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Self-citationGertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationDispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Self-citationCardiovascular Magnetic Resonance in Cardiac Amyloidosis
Maceira, A. M., Joshi, J., Prasad, S. K., Moon, J. C., Perugini, E., Harding, I., Sheppard, M. N., Poole-Wilson, P. A., Hawkins, P. N., & Pennell, D. J. (2005) · Circulation · doi:10.1161/01.cir.0000152819.97857.9d · Cited by 982
Vrana, J. A., Gamez, J. D., Madden, B. J., Theis, J. D., Bergen, H. R., & Dogan, A. (2009) · Blood · doi:10.1182/blood-2009-07-230722 · Cited by 904
Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815 · cited 1×
“In that case, the FLC : ratio or the difference between involved and uninvolved free light chains should be monitored.(20)”
BackgroundSelf-citationDiagnosis and Management of the Cardiac Amyloidoses
Falk, R. H. (2005) · Circulation · doi:10.1161/circulationaha.104.489187 · Cited by 791
Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., & Therneau, T. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361702 · Cited by 688
Self-citationMisdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis
Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., & Hawkins, P. N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013354 · Cited by 680
Kyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationSkinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H., Berk, J. L., Anderson, J. J., O'Hara, C., Finn, K. T., Libbey, C. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-2-200401200-00008 · Cited by 618
Self-citationTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070484 · Cited by 519
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
Merlini, G., & Stone, M. J. (2006) · Blood · doi:10.1182/blood-2006-03-001164 · Cited by 463
Self-citationLachmann, H. J., Gallimore, R., Gillmore, J. D., Carr‐Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 435
Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., & Buxbaum, J. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400062101 · Cited by 392
Mikhael, J. R., Schuster, S. R., Jimenez-Zepeda, V. H., Bello, N., Spong, J., Reeder, C. B., Stewart, A. K., Bergsagel, P. L., & Fonseca, R. (2012) · Blood · doi:10.1182/blood-2011-11-390930 · Cited by 375
Skinner, M., Anderson, J. J., Simms, R. W., Falk, R. H., Wang, M., Libbey, C. A., Jones, L. A., & Cohen, A. S. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89487-9 · Cited by 370
Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S.-I., Merlini, G., Saraiva, M. J. M., & Westermark, P. (2010) · Amyloid · doi:10.3109/13506129.2010.526812 · Cited by 367
Self-citationComenzo, R. L., Vosburgh, E., Falk, R. H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L. M., Berk, J. L., Akpek, G., LaValley, M., et al. (1998) · Blood · doi:10.1182/blood.v91.10.3662 · Cited by 343
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Bodin, K., Ellmerich, S., Kahan, M. C., Tennent, G. A., Loesch, A., Gilbertson, J. A., Hutchinson, W. L., Mangione, P. P., Gallimore, J. R., Millar, D. J., et al. (2010) · Nature · doi:10.1038/nature09494 · Cited by 341
Shi, J., Guan, J., Jiang, B., Brenner, D. A., del Monte, F., Ward, J. E., Connors, L. H., Sawyer, D. B., Semigran, M. J., Macgillivray, T. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912263107 · Cited by 336
Self-citationDispenzieri, A. A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., McConnell, J. P., Litzow, M. R., Gastineau, D. A., Tefferi, A., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0390 · Cited by 320
Self-citationSurvival in patients with primary systemic amyloidosis and raised serum cardiac troponins
Dispenzieri, A., Kyle, R. A., Gertz, M. A., Therneau, T. M., Miller, W. L., Chandrasekaran, K., McConnell, J. P., Burritt, M. F., & Jaffe, A. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13396-x · Cited by 317
Self-citationSipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S.-I., Merlini, G., Saraiva, M. J. M., & Westermark, P. (2012) · Amyloid · doi:10.3109/13506129.2012.734345 · Cited by 311
Self-citationPalladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A. R., D'Eril, G. M., Fogari, R., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4385 · Cited by 311
Self-citationBortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Kastritis, E., Wechalekar, A. D., Dimopoulos, M. A., Merlini, G., Hawkins, P. N., Perfetti, V., Gillmore, J. D., & Palladini, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8220 · Cited by 298
Self-citationPalladini, G. O., Russo, P., Bosoni, T., Verga, L., Sarais, G., Lavatelli, F., Nuvolone, M., Obici, L. P., Casarini, S., Donadei, S., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.117143 · Cited by 281
Self-citationPomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
Sanchorawala, V., Shelton, A. C., Lo, S., Varga, C., Sloan, J. M., & Seldin, D. C. (2016) · Blood · doi:10.1182/blood-2016-04-710822 · Cited by 275
Self-citationDispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K., Geyer, S. M., Lust, J. A., Allred, J. B., Witzig, T. E., Rajkumar, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-07-032987 · Cited by 273
Self-citationLenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S., Zeldis, J. B., Skinner, M., & Seldin, D. C. (2007) · Blood · doi:10.1182/blood-2006-07-030544 · Cited by 260
Self-citationKristen, A. V., Dengler, T. J., Hegenbart, U., Schonland, S. O., Goldschmidt, H., Sack, F.-U., Voss, F., Becker, R., Katus, H. A., & Bauer, A. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2007.10.016 · Cited by 254
Dispenzieri, A., Lacy, M. Q., Katzmann, J. A., Rajkumar, S. V., Abraham, R. S., Hayman, S. R., Kumar, S. K., Clark, R., Kyle, R. A., Litzow, M. R., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2922 · Cited by 253
Self-citationPrognostic Significance of Strain Doppler Imaging in Light-Chain Amyloidosis
Koyama, J., & Falk, R. H. (2010) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2009.11.013 · Cited by 240
Kumar, S., Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Lentzsch, S., Munshi, N., Niesvizky, R., et al. (2009) · Blood · doi:10.1182/blood-2009-04-205013 · Cited by 234
Wechalekar, A. D., Goodman, H. J. B., Lachmann, H. J., Offer, M., Hawkins, P. N., & Gillmore, J. D. (2007) · Blood · doi:10.1182/blood-2006-07-035352 · Cited by 233
Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B., & Merlini, G. (2005) · Blood · doi:10.1182/blood-2004-08-3231 · Cited by 227
Self-citationPalladini, G., Barassi, A., Klersy, C., Pacciolla, R., Milani, P., Sarais, G., Perlini, S., Albertini, R., Russo, P., Foli, A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-286567 · Cited by 224
Self-citationAmyloid Fibril Protein Nomenclature - 2002
(2002) · Amyloid · doi:10.3109/13506120209114823 · Cited by 217
Hawkins, P. N., Lavender, J. P., Myers, M. J., & Pepys, M. B. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92235-0 · Cited by 209
The spectrum of localized amyloidosis: A case series of 20 patients and review of the literature
Biewend, M. L., Menke, D. M., & Calamia, K. T. (2006) · Amyloid · doi:10.1080/13506120600876773 · Cited by 184
Sanchorawala, V., Skinner, M., Quillen, K., Finn, K. T., Doros, G., & Seldin, D. C. (2007) · Blood · doi:10.1182/blood-2007-07-099481 · Cited by 166
Self-citationReece, D. E., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G. O., Fermand, J., Vescio, R. A., Liu, X., Elsayed, Y. A., Cakana, A., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203398 · Cited by 161
Self-citationProkaeva, T. B., Spencer, B., Kaut, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22959 · Cited by 154
Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue
Lavatelli, F., Perlman, D. H., Spencer, B., Prokaeva, T. B., McComb, M. E., Théberge, R., Connors, L. H., Bellotti, V., Seldin, D. C., Merlini, G., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700545-mcp200 · Cited by 153
Self-citationSeldin, D. C., Choufani, E. B., Dember, L. M., Wiesman, J. F., Berk, J. L., Falk, R. H., O’Hara, C., Fennessey, S. A., Finn, K. T., Wright, D. G., et al. (2003) · Clinical Lymphoma · doi:10.3816/clm.2003.n.005 · Cited by 145
Self-citationPathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Sekijima, Y., Kelly, J. W., & Ikeda, S. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404155 · Cited by 139
Moreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X. P., Bridoux, F., Salles, G. A., Leblond, V., Roussel, M., Alakl, M., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294405 · Cited by 129
Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Kumar, S. K., Leung, N., & Gastineau, D. A. (2007) · Haematologica · doi:10.3324/haematol.11413 · Cited by 127
Self-citationCohen, A. D., Zhou, P., Chou, J. F., Teruya‐Feldstein, J., REICH, L. M., Hassoun, H., Levine, B. M., Filippa, D. A., Riedel, E., Kewalramani, T., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06783.x · Cited by 124
Kidney dysfunction during lenalidomide treatment for AL amyloidosis
Specter, R., Sanchorawala, V., Seldin, D. C., Shelton, A. C., Fennessey, S. A., Finn, K. T., Zeldis, J. B., & Dember, L. M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq482 · Cited by 115
Self-citationSeldin, D. C., Anderson, J. J., Sanchorawala, V., Malek, K. S., Wright, D. G., Quillen, K., Finn, K. T., Berk, J. L., Dember, L. M., Falk, R. H., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0089 · Cited by 115
Self-citationGertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Ansell, S. M., Elliott, M. A., Gastineau, D. A., Inwards, D. J., Micallef, I. N., Porrata, L. F., Tefferi, A., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704691 · Cited by 113
Self-citationBellavia, D., Pellikka, P. A., Al-Zahrani, G. B., Abraham, T. P., Dispenzieri, A. A., Miyazaki, C., Lacy, M. Q., Scott, C. G., Oh, J. K., & Miller, F. A. (2010) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2010.03.027 · Cited by 112
Sanchorawala, V., Seldin, D. C., Magnani, B., Skinner, M. M., & Wright, D. G. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705106 · Cited by 100
Self-citationBortezomib in the treatment of AL amyloidosis: targeted therapy?
Sitia, R., Palladini, G. O., & Merlini, G. (2007) · Haematologica · doi:10.3324/haematol.12136 · Cited by 95
Self-citationDietrich, S., Schönland, S. O., Benner, A., Bochtler, T., Kristen, A. V., Beimler, J., Hund, E., Zorn, M., Goldschmidt, H., Ho, A. D., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253237 · Cited by 91
Palladini, G. O., Russo, P., Milani, P., Foli, A., Lavatelli, F., Nuvolone, M., Perlini, S., & Merlini, G. (2012) · Haematologica · doi:10.3324/haematol.2012.073593 · Cited by 68
Self-citationImmunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid-Reactive Monoclonal Antibodies
Solomon, A., Weiss, D. T., & Wall, J. S. (2003) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497803322702824 · Cited by 67
Immunophenotype of neoplastic plasma cells in AL amyloidosis
Deshmukh, M., Elderfield, K., Rahemtulla, A., & Naresh, K. N. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.065474 · Cited by 31
Sudden death in nondilated cardiomyopathies: Pathophysiology and prevention
Soni, A. V., & LeLorier, P. (2005) · Current Heart Failure Reports · doi:10.1007/s11897-005-0019-x · Cited by 8
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Colby, C., Laumann, K., Zeldenrust, S. R., Leung, N., Dingli, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5724 · Cited by 1,137
Self-citationTransthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Metadata
- Authors
- Merlini, G., Seldin, D. C., & Gertz, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-10
- Volume
- 29
- Issue
- 14
- Pages
- 1924-1933
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2151246487
- Cited by
- 509
- References
- 63
- FWCI
- 17.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.